Friday, Novo Nordisk A/S NVO introduced headline outcomes from a section 2a medical trial with monlunabant, a small-molecule oral cannabinoid receptor 1 (CB1) inverse agonist.
Monlunabant, previously INV-202, was a part of the acquisition of Inversago Prescription drugs Inc. for $1.075 billion, introduced in August 2023.
Additionally Learn: European Drug Company Helps Novo Nordisk’s Blockbuster Weight-Loss Drug Wegovy For Weight problems-Associated Coronary heart Failure.
The trial investigated the efficacy and security of a once-daily 10 mg, 20 mg, and 50 mg of monlunabant in comparison with placebo on physique weight after 16 weeks in 243 folks with weight problems and metabolic syndrome.
From a baseline physique weight of 110.1 kg, all doses of monlunabant achieved a statistically important weight reduction in comparison with placebo.
After 16 weeks of therapy, folks handled with a once-daily 10 mg dose of monlunabant achieved a weight lack of 7.1 kg in comparison with a discount of 0.7 kg with a placebo.
Restricted further weight reduction was seen at larger doses of monlunabant.
The most typical antagonistic occasions within the trial have been gastrointestinal, with the overwhelming majority being delicate to reasonable and dose-dependent.
Reporting of delicate to reasonable neuropsychiatric unintended effects, primarily nervousness, irritability, and sleep disturbances, was extra frequent and dose-dependent with monlunabant in comparison with placebo.
No critical antagonistic occasions have been reported about neuropsychiatric unintended effects.
Primarily based on the outcomes, Novo Nordisk expects to provoke a bigger section 2b trial in weight problems in 2025 to additional examine dosing and the protection profile of monlunabant over an extended period in a world inhabitants.
Earlier this week, NanoVation Therapeutics introduced a multi-year partnership with Novo Nordisk to advance the event of novel genetic medicines focusing on cardiometabolic and uncommon ailments.
Novo Nordisk will obtain an outlined unique, worldwide license to make use of NanoVation’s LNP know-how for the 2 lead packages. NanoVation will obtain analysis funding and is eligible to obtain as much as roughly $600 million in up-front money, potential milestone funds, and tiered royalties on future product gross sales.
Value Motion: NVO inventory is down 5.49% at $127.48 on the final test on Friday.
Learn Subsequent:
Photograph through Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.